Eevia Health Issues New Warrants to Boost Capital
Eevia Health takes strategic steps to enhance its financial position with new warrant issuance.
Sammanfattning
Eevia Health issues 6 million new warrants to Lago Kapital Oy, aiming to raise approximately KEUR 400 for growth and profitability.
Eevia Health, a company known for its sustainable bioactive compounds, has announced a strategic financial maneuver to bolster its capital structure. The board has resolved to issue 6,000,000 new warrants (TO2) to the Finnish investment firm, Lago Kapital Oy. This move is part of a broader strategy to undertake private placements of shares, compensating for under-subscription in the last rights issue, with a target of approximately KEUR 400.
The issuance of these warrants is not merely a financial exercise but a calculated step to secure the working capital necessary for Eevia's continued growth. The company has emphasized the need for additional capital to streamline operations and meet increasing market demand. The TO2 warrants offer a cost-efficient means to raise this capital, especially after two previous rights issues fell short of full subscription.
Each warrant allows the holder to subscribe for one share at 70% of the volume-weighted average price on the Spotlight Stock Market during the subscription period from May 12 to June 9, 2025, but not less than 0.11 SEK. With a minimal charge per warrant, the financial implications for stakeholders are manageable, while the potential for capital influx is significant.
CEO Stein Ulve highlighted that these financial maneuvers align with Eevia's broader goals, including securing non-dilutive funding through an R&D loan. The company's focus on sustainable growth and profitability is evident, and this warrant issuance is a step towards achieving those goals.
Given Eevia's strategic positioning and the potential for market expansion, stakeholders might consider holding onto their investments. The company's focus on bioactive compounds and environmentally friendly practices positions it well for future growth in the health sector.
Källa
Sammanfattning
Eevia Board has decided to issue 6,000,000 new warrants (TO2) to Lago Kapital Oy, a Finnish investment firm, as part of a strategy to address shares not subscribed in the last rights issue. The aim is to raise approximately 400,000 euros, with the TO2 warrants being a smaller component of this effort. Orcator Oy, a shareholder of Eevia, will lend 6,000,000 shares to Lago Kapital Oy, and Stein Ulve, CEO of Eevia, owns Orcator Oy. Eevia needs additional working capital for streamlining operations, achieving profitability, and meeting demand. The TO2 warrants offer a cost-effective way to raise future capital. The subscription period for shares via the TO2 warrants is from May 12 to June 9, 2025, with each warrant allowing the purchase of one share at 70% of the average market price during the subscription period, but not less than 0.11 SEK. Unexercised warrants by June 11 will expire, and conditions for accelerated vesting apply in cases of control changes. The TO2 warrants are priced at 0.1 Swedish Øre each. These financial moves aim to capitalize on growth opportunities and support efforts for non-dilutive funding of approximately 550,000 euros. Eevia Health, founded in 2017, produces organic plant extracts for health supplements and operates a green-chemistry facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.
